The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: An analysis of 129 cases

Authors

  • Dr. David H. Buss,

    Corresponding author
    1. Department of Pathology, Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, North Carolina
    • Department of Pathology, Bowman Gray School of Medicine of Wake Forest University, 300 S. Hawthorne Road, Winston-Salem, NC 27103
    Search for more papers by this author
  • John J. Stuart,

    1. Department of Medicine), Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, North Carolina
    Search for more papers by this author
  • Gary E. Lipscomb

    1. Department of Pathology, Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, North Carolina
    Current affiliation:
    1. Department of Pathology, Louisiana State University School of Medicine, New Orleans, Louisiana
    Search for more papers by this author

Abstract

We have presented a retrospective study of 129 patients with platelet counts of 1,000 × 109/L or more—72 with myeloproliferative disorders (MPD), and 57 with reactive thrombocytosis (RT)—in an effort to determine the incidence of thrombohemorrhagic complications. Thrombotic disorders occurred with approximately equal frequency in the two groups, being found in three patients (4%) with MPD and three (5%) with RT when the platelet count was over 1,000 × 109/L and in 11% of the patients in each group when the platelet count was less than 1,000 × 109/L. In contrast, bleeding manifestations were more common in MPD, where 36% of patients were affected on one or more occasions versus only 4% of those with RT. However, bleeding was generally not severe, with only six patients requiring transfusions, and three of these patients had been receiving aspirin or corticosteroids when they developed severe gastrointestinal bleeding.

Ancillary